Rapid Response Revival opens Series E capital raise, following CE mark award, approving the sale of the CellAED® into Europe

Rapid Response Revival is pleased to announce that the Series E capital raise has been re-opened, following the grant of CE mark and ahead of the European rollout of the E-Commerce platform to enable sales of the CellAED® from September of this year.

Register Interest

The device is already approved for sale in New Zealand and the recent award of CE mark approves the CellAED® for sale not just in the 30 countries in the EuroZone but a group of countries outside Europe that recognise CE, such as Singapore, Malaysia, the Philippines and Brazil.

The Company will aim to raise up to AU$8.5M via the issue of 47,455 ordinary shares at AU$180 per share, with existing shareholders already committing over AU$3M to the round.

The funds raised in this round will be used as working capital for the business to continue to work towards manufacture and delivery of the initial order of 20,000 devices into the NZ market and to scale up for the deliveries into Europe.

About Rapid Response Revival Research Limited

Rapid Response Revival are the innovators behind the CellAED^® defibrillator technology – transforming everyday people into heroes.

Sudden Cardiac Arrest (SCA) has an extremely high death rate and is a leading cause of death globally, accounting for more deaths than many cancers, influenza, car accidents and house fire deaths combined. Anyone can suffer from SCA, regardless of age, gender or fitness level – including children. The current survival rate is just 2-11%.

The CellAED^® is designed to assist everyday people and medical professionals to prevent many unnecessary deaths. It is a lightweight, affordable, and personal Automated External Defibrillator (AED) solution, targeting the current government and enterprise market as well as the personal and home AED market.

Rapid Response Revival Limited seeks to improve the survival rate of SCA by making fast treatment effective, simple and affordable – restarting hearts in cardiac arrest within the critical ‘Survival Gap’ (first 4 minutes) before emergency services arrive. This increases the survival rate of SCA victims who receive defibrillation within this ‘Survival Gap’ as high as 70% and helping to bridge the gap to professional care.

A CellAED^® could empower everyone, everywhere to be a lifesaver.

CellAED^® is currently unapproved as a medical device in Australia. The Therapeutic Goods Administration (TGA), as the Australian Regulatory Authority, prohibits any “advertising” of an uncertified medical device to anyone other than Heath Care Professionals. The documents and videos contained in the Wholesale Investor portal are for SOPHISTICATED AND PROFESSIONAL INVESTORS ONLY, in accordance with sections 708(8), 708(10) and 708(11) respectively of the Corporations Act.

Register Interest